SNY catalyst calendar

Sanofi

Upcoming catalysts
18
Cash runway
Cash generating
Cash & investments
EUR 8450M
Phase 3 programs
32

Sanofi is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps on February 17, 2027. There are 18 upcoming events on record.

Sanofi generates cash from operations, so a burn-based runway figure does not apply.

Across 365 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
February 17, 2027 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps Trial Milestone Phase 3
April 21, 2027 Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function Trial Milestone Phase 1
April 28, 2027 Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) Trial Milestone Phase 2
April 29, 2027 A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis Trial Milestone Phase 4
May 18, 2027 A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration Trial Milestone Phase 1/Phase 2
June 7, 2027 Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age Trial Milestone Phase 3
June 21, 2027 Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Trial Milestone Phase 2
October 13, 2027 A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Trial Milestone Phase 1/Phase 2
March 13, 2028 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China Trial Milestone Phase 3
May 3, 2028 Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older Trial Milestone Phase 1/Phase 2
June 16, 2028 A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Trial Milestone Phase 2
July 3, 2028 Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older Trial Milestone Phase 2
October 26, 2028 Phase 1b/2 Study of IV Sarilumab in Adult With RA Trial Milestone Phase 1/Phase 2
February 28, 2029 A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 Trial Milestone Phase 1/Phase 2
June 19, 2029 Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne Trial Milestone Phase 1/Phase 2
November 27, 2029 Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial Milestone Phase 3
January 29, 2031 Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study Trial Milestone Phase 2
August 29, 2033 Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration Trial Milestone Phase 2

Track SNY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open SNY in the tracker

Recent history

DateEventTypePhase
October 14, 2026 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Trial Milestone Phase 3
October 1, 2026 6-K filed: Foreign issuer report Filing —
September 17, 2026 6-K filed: Foreign issuer report Filing —
September 14, 2026 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Trial Milestone Phase 3
August 6, 2026 6-K filed: Foreign issuer report Filing —
July 30, 2026 6-K filed: Foreign issuer report Filing —
July 30, 2026 6-K filed: Foreign issuer report Filing —
July 27, 2026 6-K filed: Foreign issuer report Filing —
July 17, 2026 6-K filed: Foreign issuer report Filing —
July 7, 2026 6-K filed: Foreign issuer report Filing —
June 24, 2026 6-K filed: Foreign issuer report Filing —
June 22, 2026 6-K filed: Foreign issuer report Filing —
June 12, 2026 6-K filed: Foreign issuer report Filing —
June 8, 2026 6-K filed: Foreign issuer report Filing —
June 8, 2026 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) Trial Milestone Phase 3
June 8, 2026 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) Trial Milestone Phase 3
May 27, 2026 6-K filed: Foreign issuer report Filing —
May 5, 2026 6-K filed: Foreign issuer report Filing —
April 29, 2026 6-K filed: Foreign issuer report Filing —
April 27, 2026 6-K filed: Foreign issuer report Filing —
April 23, 2026 6-K filed: Foreign issuer report Filing —
April 21, 2026 Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults Trial Milestone Phase 1
April 16, 2026 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older Trial Milestone Phase 1/Phase 2
April 15, 2026 6-K filed: Foreign issuer report Filing —
March 31, 2026 6-K filed: Foreign issuer report Filing —
March 24, 2026 6-K filed: Foreign issuer report Filing —
March 10, 2026 6-K filed: Foreign issuer report Filing —
March 4, 2026 6-K filed: Foreign issuer report Filing —
March 3, 2026 6-K filed: Foreign issuer report Filing —
March 2, 2026 Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.